Talquetamab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 138 publications

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review.

The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review.

Journal: American journal of hematology

Published: March 19, 2026

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis.

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis.

Journal: Annals of hematology

Published: January 21, 2026

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Journal: European journal of haematology

Published: January 09, 2026

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care.

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care.

Journal: Journal of medical economics

Published: January 03, 2026

Advances in the clinical application of bispecific antibodies in cancer therapy.

Advances in the clinical application of bispecific antibodies in cancer therapy.

Journal: iScience

Published: January 01, 2026

Reshaping multiple myeloma treatment: recent breakthroughs.

Reshaping multiple myeloma treatment: recent breakthroughs.

Journal: Expert opinion on pharmacotherapy

Published: December 25, 2025

Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.

Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.

Journal: British journal of haematology

Published: December 10, 2025

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Journal: The New England journal of medicine

Published: December 08, 2025

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

On-target, off-tumor oral toxicities of talquetamab in heavily pretreated multiple myeloma.

On-target, off-tumor oral toxicities of talquetamab in heavily pretreated multiple myeloma.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: December 02, 2025

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Journal: Leukemia & lymphoma

Published: December 02, 2025

Showing 1-12 of 138

Last Updated: 04/28/2026